Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Report 2026

The recombinant human granulocyte colonystimulating factor injection rhgcsf market size has grown strongly in recent years. It will grow from $3.89 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising global chemotherapy treatment volumes, increasing incidence of neutropenia cases, expansion of oncology treatment centers, historic adoption of colony stimulating factors, strong clinical guideline support for GCSF use.

The recombinant human granulocyte colonystimulating factor injection rhgcsf market size is expected to see strong growth in the next few years. It will grow to $5.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growing cancer prevalence rates, higher demand for long acting injectables, expansion of biosimilar drug approvals, rising access to specialty biologics, increasing hospital supportive care protocols. Major trends in the forecast period include growth in biosimilar GCSF injections, expansion of prefilled syringe formats, higher adoption in chemotherapy support care, long acting pegylated formulation demand, increased combination supportive therapy use.

The rising incidence of neutropenia is anticipated to drive the growth of the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market going forward. Neutropenia is a medical condition characterized by abnormally low neutrophil counts, a type of white blood cell vital for combating infections, making individuals highly susceptible to bacterial and fungal infections. The increasing occurrence of neutropenia is largely due to the expanded use of intensive chemotherapy regimens for cancer treatment, as contemporary oncology protocols employ more aggressive dosing to enhance patient survival, which in turn elevates the frequency and severity of chemotherapy-induced bone marrow suppression. Recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) helps manage neutropenia by stimulating bone marrow to proliferate and differentiate neutrophil precursors, accelerating the release of mature neutrophils into the bloodstream, thereby reducing the severity and duration of neutropenia and lowering infection risks for affected patients. For example, in February 2025, the UK Health Security Agency (UKHSA), a UK government body, reported that febrile neutropenia (FN) or other infection manifestations in immunocompromised hosts without a clear anatomical site accounted for 206 cases, representing 1.4% of all community diagnoses. Hence, the rising incidence of neutropenia is fueling the growth of the rhG-CSF market.

Leading companies operating in the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market are focusing on developing innovative formulations such as PEG-free recombinant G-CSF fusion proteins to extend drug half-life, reduce injection frequency, and improve patient compliance while effectively preventing chemotherapy-induced neutropenia. PEG-free recombinant G-CSF fusion proteins are engineered molecules that combine G-CSF with a human Fc fragment without using polyethylene glycol (PEG), which extends the drug’s half-life, enhances stability, and reduces injection frequency, thereby improving patient compliance and effectively boosting neutrophil production to prevent chemotherapy-induced neutropenia. For example, in November 2024, Evive Biotech Co. Ltd., a China-based biopharmaceutical company, and APOGEPHA Arzneimittel GmbH, a Germany-based pharmaceutical company, launched Ryzneuta (Efbemalenograstim alfa Injection), an innovative long-acting, PEG-free rhG-CSF product in the German market. Ryzneuta is produced using Chinese Hamster Ovary (CHO) cells, ensuring a mammalian glycosylation pattern, and functions by binding to the G-CSF receptor to stimulate survival, proliferation, and differentiation of neutrophil precursors and mature neutrophils. Its unique Fc-fusion design extends its half-life, reduces injection frequency, and strengthens immune function, helping to prevent chemotherapy dose reductions or delays. The product has demonstrated efficacy and safety across multi-center, randomized, active-controlled trials and represents a significant advancement over conventional rhG-CSF injections.

In April 2023, Assertio Holdings Inc., a US-based specialty pharmaceutical company, acquired Spectrum Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, Assertio aims to expand its commercial capabilities and diversify its therapeutic portfolio by combining digital and in-person sales channels to accelerate product launches and revenue growth. Spectrum Pharmaceuticals Inc. is a US-based commercial-stage biopharmaceutical company that focuses on developing and commercializing novel oncology therapies, including the long-acting G-CSF product ROLVEDON.

Major companies operating in the recombinant human granulocyte colonystimulating factor injection rhgcsf market are Pfizer Inc., Novartis AG, Amgen Inc., Intas Pharmaceuticals Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Pharmaceuticals Ltd., Biocon Limited, North China Pharmaceutical Group Corporation, Shijiazhuang Pharmaceutical Group Co. Ltd., Emcure Pharmaceuticals Ltd., Harbin Pharmaceutical Group Co. Ltd., Reliance Life Sciences Pvt. Ltd., Jiuyuan Gene Engineering Co. Ltd., Qilu Pharmaceutical Co. Ltd., Amoytop Biotech Co. Ltd., Kexing Biopharm Co. Ltd., Sunway Biotech Co. Ltd., Apotex Inc., and Wuzhong Pharmaceutical Group Co. Ltd.

Tariffs on biologic drug substances, cold chain materials, and injectable packaging components are increasing input costs in the RHGCSF market. Import duties on active pharmaceutical ingredients and sterile syringe systems are raising production expenses for filgrastim and pegfilgrastim products. The most affected segments are biosimilar injections and prefilled syringe formats that depend on cross border supply chains. Regions relying on imported biologic intermediates, especially in Asia Pacific and Latin America, are seeing price pressure. Companies are responding by localizing fill finish operations and regional sourcing. In some countries, tariff barriers are encouraging domestic biologics manufacturing capacity. This is supporting local players and improving regional supply security over time.

The recombinant human granulocyte colonystimulating factor injection rhgcsf market research report is one of a series of new reports that provides recombinant human granulocyte colonystimulating factor injection rhgcsf market statistics, including recombinant human granulocyte colonystimulating factor injection rhgcsf industry global market size, regional shares, competitors with a recombinant human granulocyte colonystimulating factor injection rhgcsf market share, detailed recombinant human granulocyte colonystimulating factor injection rhgcsf market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant human granulocyte colonystimulating factor injection rhgcsf industry. This recombinant human granulocyte colonystimulating factor injection rhgcsf market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recombinant human granulocyte colony-stimulating factor injection (RHGCSF) is a biological medication developed to stimulate the growth and maturation of neutrophils in bone marrow, thereby enhancing immune defense. It includes a recombinant form of human granulocyte colony-stimulating factor that lowers infection risk in patients experiencing neutropenia due to chemotherapy, bone marrow transplants, or specific blood disorders.

The primary types of recombinant human granulocyte colony-stimulating factor injections RHGCF include filgrastim and lenograstim. Filgrastim is a recombinant protein designed to promote neutrophil production to prevent or manage neutropenia in patients receiving chemotherapy or undergoing bone marrow transplantation. These injections are delivered through administration routes such as subcutaneous injection and intravenous injection. They are prescribed for patient groups including pediatric patients and adult patients. They are used across indications such as cancer and bone marrow disorders and are supplied through hospital pharmacies and retail pharmacies.

The recombinant human granulocyte colony-stimulating factor injection (RHGCSF) market consists of sales of injectable formulations, prefilled syringes, filgrastim injections, pegfilgrastim injections, lenograstim injections, biosimilar filgrastim injections, and biosimilar pegfilgrastim injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.